260
Participants
Start Date
April 22, 2020
Primary Completion Date
December 31, 2025
Study Completion Date
August 31, 2026
CHS-388
CHS-388 is a fully human IgG1 antibody against IL-27. Inhibition of IL-27 with CHS-388 reduces STAT1 phosphorylation leading to increased pro-inflammatory (anti-tumor) cytokine secretion (e.g., IFN-g, TNF-a) and decreased expression of inhibitory immune checkpoint receptors (e.g., PD-L1, TIGIT, LAG3) on immune cells that may result in anticancer therapeutic activity.
Pembrolizumab
Pembrolizumab by intravenous (IV) infusion
Toripalimab
Toripalimab by IV infusion
Icahn School of Medicine at Mount Sinai (ISMMS) - The Mount Sinai Hospital (MSH), New York
Roswell Park, Buffalo
University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center (University of Pittsburgh Cancer Institute (UPCI)), Pittsburgh
University of Miami Leonard M. Miller School of Medicine (UMMSM), Miami
Vanderbilt University Medical Center (VUMC), Nashville
Cleveland Clinic, Cleveland
University of Michigan Health System (UMHS), Ann Arbor
Washington University School of Medicine - St. Louis, St Louis
University of Oklahoma Health Sciences Center (OUHSC) - Stephenson Cancer Center, Oklahoma City
University of Texas Southwestern Medical Center, Dallas
The University of Texas - MD Anderson Cancer Center, Houston
South Texas Accelerated Research Therapeutics, San Antonio
University of Southern California (USC) - Norris Comprehensive Cancer Center, Los Angeles
City of Hope, Duarte
UCSF Medical Center - Helen Diller Family Comprehensive Cancer Center, San Francisco
National University Hospital, Singapore
National Cancer Center Singapore (NCCS), Singapore
Dana Farber Cancer Institute, Boston
Seoul National University Hospital, Seoul
Severance Hospital, Seoul
Asan Medical Center, Seoul
Lead Sponsor
Merck Sharp & Dohme LLC
INDUSTRY
Coherus Oncology, Inc.
INDUSTRY